Women-only drug treatment services and needs in Iran: the first review of current literature by Zahra Alam-mehrjerdi et al.
REVIEW ARTICLE Open Access
Women-only drug treatment services and
needs in Iran: the first review of current
literature
Zahra Alam-mehrjerdi1, Reza Daneshmand2*, Mercedeh Samiei3, Roya Samadi4, Mohammad Abdollahi5
and Kate Dolan1
Abstract
Background: Iran (Persia) has a women-only drug treatment system. However, literature is not documented.
The current study aimed to review the development of women-only drug treatment and harm reduction services
(WODTHRS) and the factors associated with treatment entry and outcomes in Iran. The review was based on a
comprehensive search for all literature focusing on WODTHRS in Iran.
Methods: Data were collected by conducting systematic searching of scientific English and Persian databases and
grey literature. This was done in line with Cochrane Guideline for conducting systematic reviews. Overall, 19,929
studies were found. But, only 19 original studies were included after excluding non-relevant studies.
Results: The review findings indicate how WODTHRS have been developed in the past 15 years. The review
findings underscore the roles of numerous factors in treatment entry such as the side effects of illicit drug use.
In addition, cognitive-behavioral interventions, methadone treatment and some factors outside drug treatment
such as family support increase positive treatment outcomes among women.
In contrast, financial problems as well as other factors such as insufficient medical, psychiatric and social work
services hamper treatment entry and positive treatment outcomes.
Conclusions: The review results highlight that eliminating barriers to treatment entry and positive treatment
outcomes should be addressed. Conducting randomized controlled trials is needed to evaluate the effectiveness of
WODTHRS. This issue should address the factors influencing service utilization to incorporate the best practice for
women. The evaluation of the long-term efficacy of WODTHRS is a critical research gap which should be addressed
in future studies.
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Background
The origins of illicit drug use
Smoking opium has a long history in Iran which dates
back hundreds of years before the tribal Arab invasion
to Iran. At the time of Zoroaster, the Persian prophet,
the use of some plants with euphoric effects was the
main part of religious ceremonies among the Persians.
Persian physicians such as Zakariya-al-Razi and
Avicenna were among the first scientists who used
opium for surgery. Iran has remained a transit and con-
sumer country for opiates because of Afghanistan, the
main opium producer through the centuries [1].
The current prevalence of illicit drug use
The total number of regular and recreational substance
users is estimated to be between four and seven million
[1]. It is estimated that 1,200,000-2,000,000 people are
dependent on illicit drugs mainly inexpensive Afghan
opium, heroin and/or methamphetamine [1, 2]. The
main route of drug use is smoking [1, 2]. Other main
types of illicit drugs include opium residues, hashish,
tramadol and prescription opioids [1, 3, 4].
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Illicit drug use among women
According to the Ministry of Health and Medical Educa-
tion (MoHME), almost ten percent of drug-dependents
are women [5]. MoHME (2014) reported that there was
one drug-using woman per eight drug-using men in the
country. According to the report, illicit drug use is a
health concern among some women [5].
In general, women are opiate smokers or poly-smokers
of opiates and methamphetamine. But drug injection
among women is rare because of stigma [6–10]. In
addition, women with illicit drug use problem have
poorer education and employment than men [11].
Women initiate illicit drug use later than men or are
raised in poor environments with drug use problem [12].
Study objectives
The provision of a drug response has been addressed for
women in Iran [11, 13–15]. But, there is no previous
systematic review of how women-only drug treatment
and harm reduction services (WODTHRS) have been
developed. Furthermore, the motivations and barriers as-
sociated with facilitating or hampering treatment entry
and positive treatment outcomes among this group have
not been documented. The current review aimed to ad-
dress this gap in literature.
Methods
Searching procedure
The review procedure was prepared in compliance with
Cochrane Guideline for conducting systematic reviews
[16]. Data regarding the evidence of WODTHRS and
the associated motivations and barriers were collected
through a systematic literature search.
To be included in the review, years 1980–2015 were
selected for searching because of a paucity of studies of
illicit drug use before 1980. Studies were included if they
emphasized drug treatment and/or harm reduction ser-
vices for women only and their motivations and barriers
for treatment. The term “motivations” refers to reasons
that women report specialized for using drug treatment
and/or harms reduction services. The term “barriers” re-
fers to reasons that women do not report specialized for
using drug treatment and/or harm reduction services.
Studies were excluded if they were not women-only re-
search studies.
Medical Subject Headings (MeSH) of ‘women-only
drug services’ and ‘women-only harm reduction ser-
vices’ were employed. MeSH subtitle headings were
‘Iran’, ‘development’, ‘treatment entry’, and ‘treatment
outcomes’. Keywords added to the search parameters
were ‘motivations’, ‘barriers’, ‘utilization’, and ‘access’.
Searches in Google Scholar employed the phrases ‘drug
treatment in Iran’, ‘harm reduction in Iran’, ‘women-only
drug treatment services in Iran’, and ‘access to drug
treatment and harm reduction for women in Iran’.
Based on the Guideline, English publications were
retrieved through searching Web of Sciences, Medline,
EMBASE, PubMed citation indexes, CINHAL, Scopus
and Google Scholar. In addition, scientific Persian
databases including Scientific Information Database,
Magiran, Iran Medex and the website of the confer-
ence papers of Iran were searched.
Based on the Guideline, part of the searching included
grey literature. This included the regional reports of the
United Nations Office on Drugs and Crime, the confer-
ence abstract books of Harm Reduction Association, the
National Institute on Drug Abuse and the College on
Problems of Drug Dependence. The reports of MoHME
and the Persian Welfare Organization were also searched.
Search findings
Systematic searching resulted in finding 19,929 English
and Persian articles, reports and conference papers.
Overall, 19 relevant studies were included. Most of the
studies were related to English papers indexed in Pub
Med or grey literature. Seven studies were related to
the development of WODTHRS. Overall, 12 studies
were related to treatment motivations and barriers. Du-
plicates such as editorials were excluded from the final
searching (See Fig. 1).
Results
The development of drug treatment services
Gender-mixed drug treatment clinics were established
for the first time between 1974 and 1977 that provided
methadone treatment. Over the same time, 30,000 her-
oin and opium-dependents were on methadone pro-
gram. But, because of Islamic views, illicit drug use was
considered as a criminal activity between 1979 and
2000. Therefore, methadone treatment was not pro-
vided [1, 17, 18].
The western health policy of drug treatment was re-
approved by the government in 2000 [1]. This was the
result of considering illicit drug use as a health concern
and the collaboration of the medical sector with the
government. According to a recent MoHME report,
more than 500,000 clients have received medication-
assisted treatment (MAT) programs at 3,373 drug treat-
ment centers [13].
The development of women-only services
According to a recent report from the Welfare
Organization, almost ten percent of people seeking
treatment at drug treatment centers are women [19].
Women’ needs for drug treatment motivated some
health policy makers to approve women-only drug ser-
vices in the community [19].
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The presence of some at-risk women in the commu-
nity was also a motivation to approve WODTHRS.
Stigma was another motivation to develop such services.
A survey at eight main methadone clinics in Tehran
found that only four percent of the clients were women
[20]. Some women reported unwillingness to seek pro-
fessional help at methadone treatment centers because
of social stigma [20].
The idea of developing WODTHRS was initiated in
Shiraz city near the Persian Gulf in 2001. This issue was
supported by the Welfare Organization and the govern-
ment [5]. The first women-only residential center was
established by Rebirth Society (NGO) in the same city in
2002. The treatment program included 12-step meetings
and a faith-based intervention. Over the same time
period, “Chitgar” therapeutic community center was
established by Rebirth Society in Tehran to admit
women from all-over Iran [1].
In addition, “Khaneye khorshid” drop in center was
established in Tehran in 2006. The center provides
methadone maintenance treatment and free harm re-
duction services for women [1]. The first women-only
methadone clinic (i.e., Persepolis clinic) was estab-
lished in Tehran in 2007 [8]. Two studies at the same
clinic found that only 20 % of the women reported
lifetime drug treatment [9] and they needed metha-
done treatment [10].
Over the same time, some women especially in low
socio-economic areas reported opiate dependence. This
issue necessitated more opiate treatment. Therefore,
some women-only therapeutic community and MAT
programs were developed throughout the country after
2007 [11–13, 21],
Illicit drug use also led to engagements with high risk
behaviors among some women which necessitated a
specific response. Therefore, harm reduction services
have been provided for at-risk women at women-only
centers since 2007. Some of these centers include
Atabak, Parniyan, Nader, Navid-e-Hamrazi-e-Iranians
and Mikhak clinics in Tehran and other cities. The ser-
vices have been based on the simultaneous provision of
drug treatment and harm reduction programs [5].
The success of these centers in admitting women and
the provision of WODTHRS encouraged some health
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Fig. 1 The flowchart of systematic searching
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policy makers to develop similar centers. Therefore, a
center for at-risk women was established in Shiraz and
Esfahan near the Persian Gulf of Iran in 2007. A study
found that most of the women at the center were
smokers of opiates. Women needed regular visits by
infectious diseases specialists and methadone treat-
ment. Women needed other treatment services such
as an increase in the duration of receiving women-
only services [21].
Furthermore, the government attempted to provide
more free services for at-risk women. Therefore, five
women-only harm reduction centers were established in
five provinces between 2007 and 2008. Specific groups
of women such as female injecting drug users were
admitted at the centers [14] (See Table 1).
A survey found that 442 women were admitted at
the centers by March 2008. Overall, 27.1 % of them
reported high risk sexual behaviors. Overall, 11.3 % of
them were injecting drug users. Methadone mainten-
ance treatment, harm reduction programs such as
HIV education and condom promotion were the most
provided services. Overall, more than 5,000 drug
treatment and harm reduction services were provided
for the clients [14] (See Fig. 2).
There were 29 registered women-only centers in the
main cities by the end of April 2014. More than 6,000
women were voluntarily admitted at the centers between
2007 and 2014. A national survey found that 2,100
women were admitted at least once at the centers to
receive free WODTHRS by the end of April 2014 [14, 15].
Approximately, 45 % of women were maintained on
methadone program. Counselling sessions were pro-
vided for all women. In addition, outreach teams
distributed 22,000 condoms and 7,500 syringes among
3,500 at-risk women in the community. Overall, 1,762
syringes, 38,000 male condoms and 2,500 female con-
doms were distributed among women and their part-
ners [14] (See Table 2).
Motivation for treatment entry and positive treatment
outcomes
Drug treatment entry and positive treatment outcomes
may be increased by specific motivations among women. In
contrast, low rates of drug treatment entry and positive
treatment outcomes may emphasize specific barriers
among women. Recent women-only studies in Iran found
that the encouragement of others, an individual need to
take methadone and poor satisfaction with some drug treat-
ments were strong motivations for treatment entry [7].
A study found that the side effects of drug use, anx-
iety, depression and familial problems [22] were strong
motivations for treatment entry. Two studies found that
adequate methadone dose, as well as psychological ser-
vices, drug education [23], motivational interviewing and
life skills training [24] facilitated positive treatment
Table 1 Provided services at the centers
Clients Harm reduction STIa management Counseling Referral for VCTb
n % n % n % n %
Spouses of IDUsc 50.9 21.7 21 4.2 52 2.4 21 4.4
Spouses of prisoners 51 2.2 57 11.5 154 7.2 66 13.7
Spouses with high risk sex 10 0.4 19 3.8 394 15.8 333 6.8
Spouses of NIDUsd 52 2.2 55 11.1 149 7.0 55 11.4
IDUs 1366 58.1 51 10.3 130 6.1 61 12.7
NIDUs 201 8.5 142 28.6 245 11.5 120 24.9
Clients with high risk sex 134 5.7 123 24.8 948 44.6 83 17.2
Clients with recent imprisonment problem 28 1.2 28 5.6 54 2.5 43 8.9
Reference: Fahimfar et al. (2013) [14]
aSexually transmitted infections













































Fig. 2 Provided services at the centers. Reference: Fahimfar et al.
(2013) [14]. STI: Sexually transmitted infections
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Table 2 Studies related to the development of women-only services, drug treatment entry and outcomes







(i.e., 10 % of
illicit drug
users)
Main cities Any type of illicit
drug especially
opiates
Women-only residential centers and drop in
centers such as Chitgar center and Khaneye
khorshid were established for female drug
users and at-risk women such as female sex
workers and female injecting drug users.
Dolan et al. 2011a [8] 2007 78 The first women-only methadone
clinic, Tehran
Opiates and poly
use of opiates and
methamphetamine
The first methadone clinic was established for
women.
Dolan et al. 2011b [9] 2007–
2008
78 The first women-only methadone
clinic, Tehran
Opiates and poly
use of opiates and
methamphetamine
Only 20 % of women reported lifetime drug
treatment. Women reported poor social
functioning, depression, poor general health
and stigma.
Dolan et al. 2012 [10] 2007–
2008
78 The first women-only methadone
clinic, Tehran
Opiates and poly
use of opiates and
methamphetamine
Women who had attended the clinic
between 2007 and 2008 were followed in
2009–2010. Of the 78 women recruited, 40
women were followed seven months later.
There was a significant reduction in heroin
use at follow-up. Women needed continued
methadone treatment.
Radfar. 2013 [21] 2007 15 The first two centers for health
promotion among at-risk
women, Shiraz and Esfahan, The
Persian Gulf region
Opiates and poly
use of opiates and
methamphetamine
Women needed women-only medical, psychi-






442 The first five harm reduction
centers, five provinces
Opiates and poly
use of opiates and
methamphetamine
Women received drug treatment and harm





6,000 Five provinces Opiates and poly
use of opiates and
methamphetamine
Women received free drug treatment and
harm reduction services such as methadone,




2010 69 Sixteen methadone clinics,
Tehran
Opiates Receiving information from informant sources
in the community such as mass-media,
treatment success of relatives and friends, the
encouragement of healthy family members,
the need for keeping family and children, an
individual need to take methadone to relieve
the side effects of opiate use and poor
satisfaction with other drug treatments such









Drug withdrawal, depression, anxiety, familial






62 Ten methadone clinics, Tehran Opiates Adequate methadone dose to substitute with
opiate use, counseling sessions, group
therapy, individual psychological sessions,
family therapy and drug education on
methadone program increased positive
treatment outcomes such as treatment
retention, relapse prevention and the
improvement of general health.
Ghasemi-Arganeh
et al. 2014 [24]
2012 32 A women-only therapeutic
community center, Isfahan
Opiates Group motivational interviewing and life skills
training increased positive treatment
outcomes including the reduction of drug






500 Chitgar women-only therapeutic
community center, Tehran
Methamphetamine Family support, employment, counseling and
psychological services, having an ongoing
program for daily activities, learning
motivations to change, strategies to cope
with craving, dealing with lapse, refusal skills
and relapse prevention increased treatment
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outcomes. One study found that positive treatment
outcomes were increased by having family support, em-
ployment and a program for daily activities [25]. Fur-
thermore, three studies found that cognitive-behavioral
interventions increased positive treatment outcomes
[26–28] (See Table 2).
Barriers to treatment entry and positive treatment
outcomes
Women with poor treatment motivations or misinforma-
tion about drug treatment experience barriers to treat-
ment entry and positive outcomes during treatment [29].
Only one study found that poor treatment motivation and
Table 2 Studies related to the development of women-only services, drug treatment entry and outcomes (Continued)
outcomes including the improvement of




2009 70 Chitgar women-only therapeutic
community center, Tehran
Methamphetamine Cognitive-behavioral therapy (CBT) increased
treatment outcomes including treatment
retention and the provision of drug-free urine
specimens in treatment.
Dehghani-Firooz-Abadi
et al. 2013 [27]
2012 30 Ayandenh- Roshan women-only
therapeutic community center,
Esfahan
Opiates CBT increased positive treatment outcomes
including the provision of drug-free urine




2013 43 Four drug treatment centers and
clinics, Tehran
Methamphetamine The Matrix Model of Intensive Outpatient
Treatment (CBT) increased positive treatment
outcomes including treatment retention, the
provision of drug-free urine specimens and
the improvement of general health and psy-





2012 409 Eight districts, Esfahan, central
Iran
Opium Poor treatment motivations, insufficient
information and misconceptions about drug




2011 48 Khaneye Khorshid women drop
in center, Chitgar and Congress




Unemployment, low income, unstable
accommodation and poor vocational training,
poor physical and psychological health and
poor education were barriers to achieving
positive treatment outcomes. Service
providers emphasized the necessity of
providing social and financial supports and
health insurance for increasing positive




2011 62 Chitgar center and Khaneye
khorshid center, Tehran
Opiates and poly
use of opiates and
methamphetamine
Social stigma, poor family acceptance and
low economic status were barriers to
achieving treatment retention. Insufficient
numbers of female medical doctors and a
paucity of health counseling and educational
services, living in drug-using environments
and inadequate medical and social work
services were barriers to achieving positive
treatment outcomes such as treatment






150 A central women-only drop in
center, Tehran
Poly use of opiates
and
methamphetamine
Long duration of poly use of opiates and
methamphetamine, poor family support, poor
motivations to change methamphetamine
use, poor participation in psychological and
counseling sessions, depression, an inability
to cope with everyday life pressures and
inadequate skills to cope with
methamphetamine craving and relapse were
barriers to achieving positive treatment
outcomes such as treatment compliance and
the improved general health.
1Congress 60: a chain non-governmental organization that officially provides drug treatment and harm reduction services
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lack of sufficient information about drug use were barriers
to treatment entry [29]. Three studies found that financial
problems as well as other factors such as insufficient
women-only services were barriers to achieving positive
treatment outcomes [30–32] (See Table 2).
Discussion
Studies in western countries show that relatively low
proportions of women enter drug treatment and harm
reduction centers [33, 34]. WODTHRS create a unique
environment that focuses on women’s issues and pro-
vides a comfortable setting in which women can discuss
sensitive issues such as sex work and drug injection.
Such services support women because drug treatment
and harm reduction services traditionally tend to target
men’ needs [35, 36].
Studies of women and drug treatment have remained
undeveloped in the region that Iran has been situated
[37–40]. However, Iran has initiated research on women
and drug use in recent decades [41]. It should be noted
that the recent development of WODTHRS in Iran is not
because of the segregation of women from men [14, 15].
WODTHRS in Iran aim to address women-only needs for
drug treatment [14, 15].
Gender may not be solely the predictor of treatment
entry and positive treatment outcomes. However, certain
drug treatment and harm reduction services may have
differential impacts on treatment entry and outcomes by
gender. As the numbers of female drug users may in-
crease in Iran [14, 15], studies attempt to understand
motivations and barriers associated with treatment entry
and outcomes are needed in order to provide the most
effective drug treatment services.
The current review findings underscore the roles of
numerous factors in treatment entry. Furthermore, the
review underscores that cognitive-behavioral interven-
tions, adequate methadone dose as well as some factors
outside treatment such as employment and family sup-
port increase positive treatment outcomes. In contrast,
the review findings highlight that financial problems in
combination with some factors such as stigma hamper
treatment entry and positive treatment outcomes. Stud-
ies in the United Sates indicate that drug treatment
entry and positive treatment outcomes among women
are influenced by numerous individual and social factors
such as social stigma, poor motivations to change and
unemployment [42–44].
The highlighted role of cognitive-behavioral interven-
tions may be related to the necessity of learning
essential skills to manage drug craving and relapse. Fur-
thermore, studies show that drug treatment is more
likely to be successful if it includes both methadone
and psychological services [44]. Considering the facili-
tating factors related to treatment entry and positive
treatment outcomes, as well as the provision of CBT
should be considered by health policy makers in Iran.
The professional provision of cognitive-behavioral in-
terventions is suggested to increase positive treatment
outcomes. Mass-media and families should encourage
women for drug treatment entry and utilizing harm
reduction services in the community.
In contrast, the review results indicate that individual
and social factors such as poor motivations to change
hamper treatment entry and positive treatment out-
comes. Studies in the United States indicate that women
may encounter some barriers to treatment entry and
engaging with treatment such as poor education about
drug treatment or poor motivation to change drug use
behaviors [34, 42–44]. The elimination of the barriers to
treatment entry and positive treatment outcomes should
be targeted by health policy makers in Iran.
It should be noted that programs with good treatment
outcomes are those programs that can keep clients in
treatment for long time periods [34, 44]. In addition,
longer drug treatment episodes are related to positive
treatment outcomes. Funded ancillary psychiatric, med-
ical and social work services are needed to increase
positive treatment outcomes among women in Iran. In
addition, such programs are needed to address special
needs of at-risk women such as trauma, rape or poly
drug use [45, 46].
Conclusion
The current review has a main limitation. The study is
only based on reviewing the development of WODTHRS
with an emphasis on treatment entry and outcomes in
general. Conducting further reviews with an emphasis
on cultural, social and ethnic barriers to drug treatment
especially among women in rural areas is primarily
required.
WODTHRS in Iran have been developed to address
women’ needs. But, the development of similar services
for women is still required. Enriching women-only ser-
vices with enhancements such as psychiatric and em-
ployment services may increase treatment entry and
positive treatment outcomes. The evaluation of the
efficacy of WODTHRS versus gender-mixed services is
primarily suggested. The main research gap is the long-
term efficacy of WODTHRS which should be addressed
with conducting more studies in future. Such evaluations
are needed to recruit representative samples of women
with longitudinal follow-ups.
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